Analysis reveals limited evidence on use of cannabis products in children with cancer

A recent analysis of all relevant published studies reveals a lack of evidence to determine the dosing, safety, and efficacy of medical marijuana or cannabis-containing products for managing symptoms experienced by children with cancer.

Marinomed Biotech AG sets price range for potential 10% capital increase and potential second capital increase, in each case excluding statutory subscription rights – Biotech Investments

Marinomed Biotech AG / Key word(s): Corporate Action Marinomed Biotech AG sets price range for potential 10% capital increase and potential second capital increase, in

September 16, 2024

AI drug firm Recursion moves from survival to industry domination

SALT LAKE CITY — On paper, Recursion Pharmaceuticals shouldn’t have worked. The company — or, at least, what existed at its founding in 2013 — hoped

August 19, 2024

EXS-617 by Exscientia for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.